Cobra Biologics receives £1.5 million for AAV manufacturing

Cobra Biologics, Pall, and Cell and Gene Therapy Catapult have received £1.5 million from Innovate UK to investigate continuous manufacturing of adeno-associated virus for gene therapies.
Pall Corporation, a supplier of filtration, separation and purification products, and research organization Cell and Gene Therapy Catapult will work with Cobra to develop analytical techniques and manufacturing approaches to increase process yields.
Mario Philips, vice president, and general manager of Pall Biotech, said: “Yields for downstream processing of AAV are currently very low and the production process is costly in both time and consumables.